FDA’s Oncology Center of Excellence published a Request for Applications for projects focused on applied regulatory science research to understand factors that affect the safety and efficacy of underrepresented populations in oncology therapeutic development.
Biologic drugs play an important role in treating cancers such as breast cancer and lymphoma, but their high costs can add to the financial burden of cancer care. Now, lower-cost versions known as biosimilars are gaining ground, and a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center suggests their growing use is associated with lower costs for both insurers and patients.
